Opinion of the Transparency Council – posaconazole
At its meeting on 10 March 2025, the Transparency Council adopted opinion No. 40/2025 on the reimbursement of medicinal products containing the active substance posaconazole for indications, doses or administration methods that differ from those specified in the Summary of Product Characteristics